Show simple item record

dc.contributor.authorBuettner, S.
dc.contributor.authorBraat, A.
dc.contributor.authorMargonis, G. A.
dc.contributor.authorBrown, D. B.
dc.contributor.authorTaylor, K. B.
dc.contributor.authorBorgmann, A. J.
dc.contributor.authorKappadath, S. C.
dc.contributor.authorMahvash, A.
dc.contributor.authorJNM, I. J.
dc.contributor.authorWeiss, M. J.
dc.contributor.authorLamarca, Angela
dc.contributor.authorBell, Jon
dc.contributor.authorValle, Juan W
dc.contributor.authorHagendoorn, J.
dc.contributor.authorKoerkamp, B. G.
dc.contributor.authorSze, D. Y.
dc.contributor.authorLam, M.
dc.date.accessioned2020-06-16T11:03:16Z
dc.date.available2020-06-16T11:03:16Z
dc.date.issued2020en
dc.identifier.citationS. Buettner, A. Braat, G. A. Margonis et al. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. J Vasc Interv Radiol. 2020.en
dc.identifier.pmid32473757en
dc.identifier.doi10.1016/j.jvir.2020.02.008en
dc.identifier.urihttp://hdl.handle.net/10541/623034
dc.description.abstractPURPOSE: To report outcomes of yttrium-90 ((90)Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with chi(2) tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method. RESULTS: Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after (90)Y radioembolization (4%). CONCLUSIONS: This study provides observational data of treatment outcomes after (90)Y radioembolization in patients with unresectable ICC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jvir.2020.02.008en
dc.titleYttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysisen
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.en
dc.identifier.journalJournal of Vascular and Interventional Radiologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record